Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6844312

Title:Production of tyrosine hydroxylase positive neurons
Inventors:Weiss, Samuel; Calgary, Canada
Summary:Described herein are methods of producing tyrosine hydroxylase (TH) positive neurons by differentiation from the neural stem cell. The invention relates to a method of producing neurons that express the TH enzyme by subjecting neural stem cells to FGF-1, a protein kinase A activator, a protein kinase C activator, and dopamine/L-DOPA. Also described are methods in which forskolin is used as a protein kinase A activator, thereby requiring only low levels of FGF-1 and forskolin to efficiently produce TH positive neurons from fetal or adult neural stem cells. Further disclosed are compositions used to produce TH positive neurons and the resulting neural cell culture. Also included are therapeutic applications in the treatment of diseases which are associated with dopamine neuron loss or dysfunction, such as Alzheimer's disease, Parkinson's disease, schizophrenia or clinical depression.
Abstract:The present invention relates to a method of producing neurons that express the enzyme tyrosine hydroxylase (TH) by subjecting neural stem cells to FGF-1, a protein kinase A activator, a protein kinase C activator, and dopamine/L-DOPA. Surprisingly, when forskolin is used as a protein kinase A activator, it requires only low levels of FGF-1 and forskolin to efficiently produce TH positive neurons from fetal or adult neural stem cells. Also provided are compositions used to produce TH positive neurons and the resulting neural cell culture, as well as a method of treating disease or conditions which are associated with dopamine neuron loss or dysfunction.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6844312
Application Number:US2002000118167
Date Filed:09/04/2002
Date Published:18/01/2005
Assignee:Stem Cell Therapeutics Inc., Calgary, Canada


 
Copyright © 2007 The Institute for Cellular Medicine  6/13/2021